The present invention relates to a method for identifying ?T-cell (or ?T-cell) receptors chains or parts thereof that mediate an anti-tumor or anti-infection response by identifying amino acid sequences comprising ?T-cells (or ?T-cell) receptors chains or parts thereof that are shared between different donors.

Described herein are methods for selecting lymphocytes for adoptive cell therapy based on P-glycoprotein expression and compositions comprising same.

The present disclosure provides compositions and methods for targeting a minor histocompatibility (H) antigen (HA-1.sup.H) to, for example, prevent or manage relapse of a hematological malignancy after allogeneic hematopoietic stem cell transplantation (HCT). Also provided are transgene constructs encoding engineered binding proteins, such as a T cell receptor or a chimeric antigen receptor, optionally encoding additional components such as a co-receptor and/or safety switch. Such transgene constructs can be transduced into an immune cell, such as a T cell, and used as an immunotherapy in a subject having a hematological malignancy or at risk for recurrence of the hematological malignancy (e.g., leukemia, lymphoma, myeloma).

A chimeric antigen receptor targeting to CD47, its encoding sequence, and its modified immune response cells, and the preparation and application thereof. The present invention constructs a chimeric antigen receptor targeting to CD47 and its modified immune response cells based on the SIRP molecule, and the novel modified immune response cells can effectively target a variety of tumor cells, and can be used to prepare preparations for the treatment of tumors, especially the preparations for inhibiting the expression of CD47-positive tumor cells. The preparation of the modified immune response cells of the target CD47 is easy, and the modified immune response cells of the target CD47 have high killing rate on tumor cells.

Provided herein are cell populations transiently expressing a chimeric antigen receptor (CAR) and their use in the chronic treatment of hyperproliferative diseases such as cancer.

Disclosed herein are methods for generating universal MHC/HLA-compatible hematopoietic progenitor cells and methods for generating custom patient-specific MHC/HLA-compatible hematopoietic progenitor cells. Compositions comprising the universal and custom hematopoietic progenitor cells and therapeutic applications thereof are also disclosed.

Described herein are anti-CD277 antibodies which: activates or inhibit the cytolytic function of V?9/V?2 T cells, and/or costimulates T cells together with CD3-TCR, and/or costimulates T cells in addition to CD28-B7 costimulation, and/or increases the activity and/or survival of monocytes and dendritic cells. The use of said antibodies in therapy is also described.

This disclosure provides miRNA/mRNA pairs that can be used to increase the efficacy of T cells or to down-modulate T cell efficacy and restore equilibrium.

The present invention relates to retroviral particle comprising a protein derived from the Gag polyprotein, an envelope protein, optionally an integrase and at least two encapsidated non-viral RNAs, the encapsidated non-viral RNAs each comprising an RNA sequence of interest bound to an encapsidation sequence, each encapsidation sequence being recognized by a binding domain introduced into the protein derived from the Gag polyprotein and/or into the integrase, and at least one of said sequences of interest of the encapsidated non-viral RNAs comprises a part coding at least one epitope and/or at least one molecular structure specifically recognizing an epitope.

Provided are CD4+ T-cell-based compositions and methods for treating hypertension.